Nisolon is commonly used for conditions involving inflammatory processes of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. This application is relevant across therapeutic areas where short-term symptom management is appropriate, including various steroid-responsive indications.

Managing Acute Ocular Inflammation

This medication is applied across domains where additional symptomatic support is needed to address acute or pronounced inflammatory episodes. It is commonly used to help with conditions like anterior uveitis (iritis and cyclitis), specific forms of keratitis, and severe allergic conjunctivitis. The medication is used to address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort, burning, and irritation, which helps ease the overall symptom burden during acute episodes.

Supporting Postoperative and Traumatic Recovery

The medication is relevant in clinical settings that involve acute or unstable symptom patterns following disruptive events. It is often used during the phase after eye surgery (e.g., cataract extraction) when supportive symptom management is appropriate, and in scenarios resulting from ocular trauma or chemical exposure. By helping to ease these symptoms, the drug contributes to improved comfort during periods of heightened physical distress.

---

Quick Fact: Symptomatic Support for Ocular Discomfort

Nisolon is considered relevant for easing symptoms that interfere with daily comfort, specifically symptoms related to physical discomfort and irritative states, when symptoms create noticeable functional strain.

Regulatory References

1. DailyMed official labeling from the NIH

Who can and cannot use Nisolon? — Official Regulatory Information

This section defines the official population eligibility and non-eligibility rules for Nisolon (Prednisolone Acetate Ophthalmic Suspension), strictly according to government regulatory labeling.

Absolute Non-Eligibility (Contraindications): Nisolon is strictly contraindicated and must not be used by patients with:

• Known or suspected hypersensitivity to the active ingredient or any excipients.
• Most active viral diseases of the cornea and conjunctiva, including Epithelial Herpes Simplex Keratitis (dendritic keratitis).
• Active Mycobacterial or Fungal diseases of the ocular structures.
• Acute untreated purulent ocular infections.

Conditional and Restricted Use:

• Glaucoma: Use requires caution and frequent monitoring of intraocular pressure (IOP).
• Corneal Thinning: Use is restricted due to the potential risk of globe perforation.
• History of Herpes Simplex: Use demands great caution and mandatory, frequent ophthalmological examination.

Age and Reproductive Status:

• Adults and the Geriatric population have established use profiles. However, eligibility is not established or not recommended for certain pediatric populations by various authorities.
• Pregnancy: Use is conditional, permitted only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding: Use is not recommended due to the unknown risk of systemic absorption causing adverse effects in the infant.

Interactions with other medicines and products

The official regulatory profile for Nisolon (Prednisolone Acetate Ophthalmic Suspension) is based strictly on pharmacokinetic interaction patterns related to the drug's systemic clearance. Due to the very low systemic absorption of this topical formulation, interactions are narrowly focused.

Interacting Medicines and Mechanism

The documented interaction involves agents classified as CYP3A inhibitors. Specifically, co-treatment with strong inhibitors of the CYP3A enzyme system, including Cobicistat-containing products, is identified as a clinically relevant pharmacokinetic interaction. Regulatory sources state that this interaction mechanism results in the inhibition of clearance for the small amount of systemically absorbed prednisolone.

Exposure Modification and Restrictions

This metabolic interaction leads to a formal outcome: an increase in systemic corticosteroid exposure. This documented exposure modification carries the risk of systemic side effects. Consequently, co-administration with CYP3A inhibitors should be avoided unless the potential therapeutic benefit is judged to outweigh the documented systemic risk. This is the primary interaction-related restriction documented in the official prescribing information. No specific timing-based interaction rules or interactions with food, alcohol, or herbal products are explicitly documented in regulatory labeling for this ophthalmic suspension.

How Nisolon Works

The mechanism of action for Nisolon, which contains the synthetic glucocorticoid Prednisolone Acetate, is centered on suppressing the biological cascade of inflammation by altering gene regulation.

---

Gene-Level Control via the Glucocorticoid Receptor

The drug acts as an agonist for the Glucocorticoid Receptor (GR), initiating a complex that moves into the cell nucleus. This complex engages the cell's gene-regulating machinery, achieving transrepression (inhibition) of pro-inflammatory transcription factors like NF-kappa B. This action limits the expression of genes for cytokines and chemokines, thereby modulating signals that promote sustained cellular activity and recruitment.

---

Inhibiting Mediator Synthesis and Cell Migration

A downstream genomic effect is the induction of Annexin A1, an anti-inflammatory protein that indirectly inhibits the enzyme Phospholipase A2. Blocking this enzyme upstream halts the entire Arachidonic Acid Cascade, thereby preventing the formation of inflammatory mediators like prostaglandins and leukotrienes. Simultaneously, the mechanism stabilizes vascular integrity and limits the expression of adhesion molecules, inhibiting the migration of immune cells, such as leukocytes, into the ocular tissues. This physiological stabilization limits the ingress of fluid and cells, resulting in reduced tissue fluid accumulation (edema).

---

Mechanism Constraints

Because the drug's core action relies on gene transcription and the subsequent synthesis and depletion of proteins, the maximum physiological effect is delayed and not immediate. Furthermore, the mechanism exclusively addresses the host's inflammatory response, and possesses no intrinsic activity against any underlying causative agents.

How to use Nisolon — Administration Overview

Nisolon (prednisolone) is a corticosteroid typically administered orally. The dosage and regimen are highly variable and must be strictly individualized based on the patient's response and disease severity. The initial dose usually ranges from 5 mg to 60 mg daily for adults, which is then gradually reduced to the lowest effective maintenance dose once a satisfactory response is achieved.

Procedural and Dosing Rules

Administration Scope	Standard Administration
Route & Timing	Oral. Must be taken with food (e.g., after breakfast) to minimize gastrointestinal irritation.
Dosing Schedule	Initial dose must be maintained or adjusted until a clinical response is noted, then decreased in small increments. The daily dose may be given as a single morning dose or in divided doses.
Alternate-Day Therapy	An alternate-day regimen (a single dose every other morning) is an acceptable strategy for some patients requiring long-term treatment, as it may help reduce adrenal suppression.
Preparation	Tablets should be swallowed whole (not broken or crushed), unless scored for division. Liquid forms must be measured using the provided dosing device.
Missed Dose	If a dose is missed, take it as soon as possible. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular schedule. Do not double the dose.
Discontinuation	The drug must not be stopped suddenly if it has been taken long-term (e.g., more than three weeks) or at high doses. The dose must be gradually tapered down under medical supervision to avoid acute adrenal insufficiency.

For pediatric use, the dosage should be guided by clinical response rather than strictly by age or body weight. Consult your healthcare provider for precise dosage instructions.

Research Evidence / Overview of Studies for Nisolon

---

Evidence from Trials for Acute Anterior Uveitis (Iritis/Cyclitis)

The research used to evaluate Nisolon (Prednisolone Acetate ophthalmic suspension) for inflammation of the anterior eye structures, such as iritis and cyclitis, includes randomized controlled trials (RCTs), systematic reviews, and regulatory evidence assessments. These studies explored conditions characterized by periods of heightened symptoms, focusing on non-infectious uveitis. Researchers in these trials was studied for outcomes related to the severity of the inflammatory process, using clinical measurements that track the number of inflammatory cells within the front chamber of the eye. This approach is used in research exploring how symptoms change over time during an acute episode.

In these research settings, studies monitored changes in inflammation scores across the typical short-term treatment course, which can last from two weeks up to six weeks, including a planned observation phase. Findings describe patterns observed in the studies where specific inflammation markers were measured during the defined time intervals. However, study protocols defining the length and phasing of the treatment period were inconsistent across trials. Furthermore, dedicated research exploring its use in children is limited, with most evidence derived from adult studies.

---

Evidence from Trials for Postoperative Ocular Inflammation

Nisolon was evaluated in short-term randomized trials that centered on patients who had undergone common surgical procedures, most often cataract extraction. The studies focused on outcomes linked to inflammatory or irritative states, specifically tracking the acute inflammatory signs (cell and flare scores) and patient-reported outcomes describing perceived discomfort. The research examined changes in the degree of inflammation during the immediate postoperative phase, with follow-up durations typically lasting only for the short, acute observational time interval (usually less than 15 days).

Key Uncertainties and Research Gaps in the Evidence

The evidence base largely consists of short-term trials, and consequently, long-term outcomes are not fully established. Research exploring the durability of observed effects—meaning whether the anti-inflammatory action lasts after the medication has been completely stopped—is limited. Additionally, comparative evidence is lacking for the use of this agent against newer or alternative anti-inflammatory treatments across all indications. Research examining specific administration frequency protocols for various patient characteristics is still emerging, and this is noted as a key uncertainty in the evidence landscape.

Key Studies & References

1. A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery (ClinicalTrials.gov: NCT00170729)

Common questions about Nisolon (FAQ)

---

Q: Does Nisolon need a prescription?

Yes. According to official regulatory documents, this type of ophthalmic suspension containing prednisolone is categorized as a Human Prescription Drug. This indicates Nisolon is dispensed only with a valid prescription from a licensed healthcare provider.

---

Q: Is Nisolon the same as Prednisone?

No, they are not the same drug. The active ingredient in Nisolon is Prednisolone Acetate. Prednisone is a related compound that the body must convert into prednisolone before it can be effective.

---

Q: What happens if I overdose on Nisolon?

Official product information generally notes that acute adverse events are not anticipated from an overdosage involving only the ocular application of the medication. If the product is accidentally swallowed, dilution by drinking fluids is the measure typically described in the labeling for this situation.

---

Q: What are the active and inactive ingredients in Nisolon?

The active ingredient in Nisolon is Prednisolone Acetate. Inactive ingredients are also included to formulate the suspension; these can include a preservative such as Benzalkonium Chloride, along with agents like boric acid and hypromellose. The complete list of ingredients is found in the official prescribing information.

---

Q: Can I wear contact lenses while using this eye drop?

Official labeling contains a caution regarding the use of soft contact lenses during treatment. This is because the medication contains a preservative that can be absorbed by the lenses. Lenses are typically directed to be removed prior to application and may often be reinserted 15 minutes following the use of the drops.

Storage

Nisolon (Prednisolone) should be stored securely in its original container, tightly closed, and kept out of the reach of children and pets. Tablets and oral solutions generally require storage at room temperature, away from excessive heat and moisture, though specific formulations may need refrigeration (check the package insert). Do not store the medication in a bathroom.

Disposal

Unused or expired Nisolon should be disposed of promptly to prevent accidental ingestion. The preferred method is to use a community drug take-back program or a drug disposal collection site, often available at local pharmacies or law enforcement facilities.

If a take-back option is not readily available, most formulations can be disposed of in the household trash. To do this, mix the medicine with an unappealing substance, such as dirt, cat litter, or used coffee grounds. Place the mixture in a sealed bag or container, and then discard it in the trash. Before discarding, always remove or obscure all personal information on the prescription label to protect privacy. Do not flush Nisolon down the toilet unless the packaging specifically instructs you to do so.